Poor
Mostly Not Aligned
Patient Risk:
Moderate
Summary
Many claims are not supported by the provided label excerpts (or cannot be verified from them). One boxed-warning-related claim is inconsistent with the supplied label content, which lists boxed warnings for All-Cause Mortality and Mortality Imbalance/Lower Cure Rates in HAP, with no boxed hepatotoxicity warning shown in the excerpts.
Category Scores
Accurate Statements
Tigecycline therapy has been associated with increases in transaminases, and some cases of significant hepatic dysfunction and hepatic failure have been reported, with monitoring/evaluation of risk/benefit of continuing therapy.
5.4 Hepatic Adverse Effects (5.4)
Unsupported Statements
Obese patients may be more susceptible to increased liver enzyme (transaminase) levels when taking tigecycline.
5.4 excerpt does not mention obesity or susceptibility by obesity status.
Tigecycline works by inhibiting protein synthesis.
12.1 Mechanism of Action excerpt provided does not state protein synthesis inhibition.
Tigecycline’s mechanism can affect the liver and result in higher levels of alanine transaminase (ALT).
5.4 states transaminase increases but the excerpt provided does not specify ALT or link to a mechanism.
Tigecycline’s mechanism can affect the liver and result in higher levels of aspartate transaminase (AST).
5.4 states transaminase increases but the excerpt provided does not specify AST or link to a mechanism.
Obese patients often require higher doses of tigecycline to achieve effective levels in their bloodstream.
2.1 provides a fixed regimen; 2.2 adjusts only for hepatic impairment categories. No obesity-based dosing is in the provided excerpts.
Increased tigecycline exposure can exacerbate liver-related side effects.
5.4 excerpt does not relate exposure level to side-effect severity.
Obesity is associated with increased liver volume and lipid content.
Not present in the provided label excerpts.
Increased liver volume and lipid content can lead to more liver enzyme release and higher transaminase levels.
Not present in the provided label excerpts.
Obese patients may be more likely to have underlying liver disease such as non-alcoholic fatty liver disease (NAFLD).
Not present in the provided label excerpts.
Underlying liver disease such as NAFLD can increase the risk of transaminase changes in obese patients taking tigecycline.
Not present in the provided label excerpts.
Increased transaminase levels can signal liver damage or strain.
5.4 excerpt recommends monitoring and evaluation but does not characterize transaminases as signaling 'damage or strain.'
Severe transaminase elevations leading to liver failure may require hospitalization and supportive care.
5.4 excerpt does not mention hospitalization or supportive care.
Elevated liver enzymes may necessitate tigecycline discontinuation.
5.4 excerpt discusses monitoring and risk/benefit of continuing therapy, but the provided text does not explicitly state discontinuation due to elevated enzymes.
Tigecycline discontinuation due to elevated liver enzymes may potentially impact treatment outcomes for serious infections.
No label excerpt provided states discontinuation impacts treatment outcomes.
Obesity is not an absolute contraindication to tigecycline.
4 lists hypersensitivity contraindication only in the provided excerpt; the 'obesity not a contraindication' statement is not explicitly supported.
Healthcare providers should closely monitor liver function in patients taking tigecycline who are obese.
5.4 monitoring is for patients who develop abnormal liver function tests; no obesity-specific monitoring recommendation is in the provided excerpts.
Healthcare providers should adjust tigecycline doses as needed to minimize harm when monitoring liver function.
5.4 provides monitoring/evaluation of risk/benefit; dose changes in the provided excerpts are based on hepatic impairment category (2.2), not monitoring of enzyme changes.
Alternative antibiotics with a more favorable safety profile may be considered for obese patients.
No provided label excerpt mentions alternatives or obesity-specific recommendations.
The FDA has issued warnings and black box labels regarding tigecycline’s potential for hepatotoxicity, including increased liver enzymes.
In the provided label excerpt, boxed warnings listed in 6 are All-Cause Mortality and Mortality Imbalance/Lower Cure Rates in HAP; Hepatic Adverse Effects is referenced as a warning/precaution but no boxed hepatotoxicity warning is shown.
The FDA has issued an injection warning for hepatotoxicity for Tygacil (tigecycline).
No provided label excerpt mentions an 'injection warning' for hepatotoxicity.
Contradictions
Low
AI Statement
The FDA has issued warnings and black box labels regarding tigecycline’s potential for hepatotoxicity, including increased liver enzymes.
Label Reference
6 Adverse Reactions (Boxed Warning items listed): All-Cause Mortality; Mortality Imbalance and Lower Cure Rates in Hospital-Acquired Pneumonia. Hepatic Adverse Effects is referenced under Warnings and Precautions (5.4), not shown as a boxed warning in the provided excerpts.
Important Omissions
Specific guidance from label on what to monitor/evaluate and the exact label approach for continuing therapy when abnormal liver function tests develop (risk/benefit) rather than discontinuation or dose adjustment based on enzyme changes.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements about obesity-specific susceptibility, dosing changes, discontinuation, and boxed hepatotoxicity warnings are not supported by the provided label excerpts; these could mislead clinical decision-making if treated as label-accurate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Not Aligned
Primary Issue
Boxed hepatotoxicity warning claim is not supported by the supplied boxed-warning content; many obesity/mechanism/ALT-AST/exposure/discontinuation/hospitalization statements are unsupported by the provided excerpts.
Suggested Improvement
Restrict claims to the provided on-excerpt label language (5.4 hepatic adverse effects: transaminase/bilirubin/PT increases, monitoring and evaluation of risk/benefit of continuing therapy, and that hepatic dysfunction may occur after discontinuation). Remove or rewrite unverified obesity-, mechanism-, ALT/AST-, exposure-, hospitalization/supportive care-, discontinuation-, and FDA boxed-warning hepatotoxicity assertions unless corresponding label text is provided.